Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.

doi:10.1371/journal.pone.0133219

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.

PloS one - 1 Jan 2015

Korkola James E, Collisson Eric A, Heiser Laura, Oates Chris, Bayani Nora, Itani Sleiman, Esch Amanda, Thompson Wallace, Griffith Obi L, Wang Nicholas J, Kuo Wen-Lin, Cooper Brian, Billig Jessica, Ziyad Safiyyah, Hung Jenny L, Jakkula Lakshmi, Feiler Heidi, Lu Yiling, Mills Gordon B, Spellman Paul T, Tomlin Claire, Mukherjee Sach, Gray Joe W

Abstract excerpt

We report here on experimental and theoretical efforts to determine how best to combine drugs that inhibit HER2 and AKT in HER2(+) breast cancers. We accomplished this by measuring cellular and molecular responses to lapatinib and the AKT inhibitors (AKTi) GSK690693 and GSK2141795 in a panel of 22 HER2(+) breast cancer cell lines carrying wild type or mutant PIK3CA. We observed that combinations of lapatinib plus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diamines

Share to Lapatinib

Share to Mammary Glands, Human

Share to Oxadiazoles

Share to Pyrazoles

Share to Quinazolines

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 26181325
DOI: 10.1371/journal.pone.0133219
PMCID: PMC4504492

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.PMID 26181325Read ↗

Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.Semantic proximity Read ↗

The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive ReviewSemantic proximity Read ↗

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.Semantic proximity Read ↗

Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.Semantic proximity Read ↗

Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.Semantic proximity Read ↗

HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.Semantic proximity Read ↗

Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.Semantic proximity Read ↗

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.Semantic proximity Read ↗

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.Semantic proximity Read ↗

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.Semantic proximity Read ↗

PIK3CA/AKT1 Mutations in Breast Carcinoma: a Comprehensive Review of Experimental and Clinical StudiesSemantic proximity Read ↗

Insulin receptor substrate 2 (IRS2) confers resistance to PI3K pathway inhibition in <i>PIK3CA</i> mutant breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.